


## PSN632408

<b>Cat. No.:</b>	HY-16673		
<b>CAS No.:</b>	857652-30-3		
<b>Molecular Formula:</b>	C <sub>18</sub> H <sub>24</sub> N <sub>4</sub> O <sub>4</sub>		
<b>Molecular Weight:</b>	360.41		
<b>Target:</b>	GPR119		
<b>Pathway:</b>	GPCR/G Protein; Neuronal Signaling		
<b>Storage:</b>	Powder	-20°C	3 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 50 mg/mL (138.73 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	<b>Preparing Stock Solutions</b>	1 mM	2.7746 mL	13.8731 mL	27.7462 mL
		5 mM	0.5549 mL	2.7746 mL	5.5492 mL
		10 mM	0.2775 mL	1.3873 mL	2.7746 mL
Please refer to the solubility information to select the appropriate solvent.					
<b>In Vivo</b>	<ol style="list-style-type: none"> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 40% PEG300 &gt;&gt; 5% Tween-80 &gt;&gt; 45% saline Solubility: ≥ 2.5 mg/mL (6.94 mM); Clear solution</li> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (6.94 mM); Clear solution</li> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 90% corn oil Solubility: ≥ 2.5 mg/mL (6.94 mM); Clear solution</li> </ol>				

### BIOLOGICAL ACTIVITY

<b>Description</b>	PSN632408, a selective, orally active GPR119 agonist, shows similar potency to OEA at both recombinant mouse and human GPR119 receptors (EC <sub>50</sub> =5.6 and 7.9 uM, respectively). PSN632408 can stimulate β-cell replication and improve islet graft function. PSN632408 has the potential for the research of obesity and related metabolic disorders <sup>[1][2]</sup> .
<b>In Vitro</b>	PSN632408 produces concentration-dependent increases in cAMP level with mean EC <sub>50</sub> value of 1.9 uM <sup>[1]</sup> . PSN632408 stimulates β cell replication in cultured mouse islets <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## In Vivo

PSN632408 (100 mg/kg; p.o.; daily for 14 days) suppresses food intake in rats and reduce body weight gain and white adipose tissue deposition upon subchronic oral administration to high-fat-fed rats<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Diet-induced obese (DIO) rats <sup>[1]</sup>
Dosage:	100 mg/kg
Administration:	P.o.; daily for 14 days
Result:	The mean daily food intake was decreased by 10% during the first week of dosing and 15% during the second week. Body weight gain was significantly attenuated from day 6 onward with some evidence of weight loss.

## REFERENCES

[1]. Gao J, et al. Stimulating beta cell replication and improving islet graft function by GPR119 agonists. *Transpl Int.* 2011;24(11):1124-1134.

[2]. Overton HA, et al. Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. *Cell Metab.* 2006;3(3):167-175.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA